Floatz logo

Sorafenib

Brain Cancer

Virginia Commonwealth UniversitySmall moleculePhase 2Dormant
BB
65/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
50/ 100
Competitive Position
95/ 100

Competitive context

36 Active assets in the Brain Cancer cohort.

Asset / SponsorPhaseRating
Irinotecan
University of California, Davis
Phase 2BBB
Cediranib
National Cancer Institute (NCI)
Phase 2BB
Cyclophosphamide
Essen Biotech
Phase 2BB
DIANHYDROGALACTITOL
Kintara Therapeutics, Inc.
Phase 2BB
Capecitabine
Northwell Health
Phase 2B

View all 50 →

Same molecule, other indications

Sorafenib is also rated in:

renal cell carcinomaDormant
BBB
Indicative ·
79 / 100
View asset →
SorafenibDormant
BBB
Indicative ·
75 / 100
View asset →
portal vein thrombosisDormant
BBB
Indicative ·
74 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →